TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22752550

Group type: EXPERIMENTAL
Intervention: Near-infrared cholangiography (NIRC) using 1 cm³ of indocyanine green injected intravenously prior to laparoscopic cholecystectomy
Number of subjects: 1

Group type: COMPARATOR
Intervention: Standard intraoperative cholangiography (IOC)
Number of subjects: 1
Study: 22759444

Group type: EXPERIMENTAL
Intervention: Progressors (n = 39) defined as those with serial LAVI change ≥3.5 mL/m(2) and baseline LAVI between 20 and 34 mL/m(2)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Changes in LAVI in 'Progressors'
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Baseline clinical associates of LAVI progression
Number of subjects: 518
Study: 22760009

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a and ribavirin for up to 48 weeks
Number of subjects: 401
Study: 22760567

Group type: EXPERIMENTAL
Intervention: Insulin (during hyperinsulinemic euglycemic clamp)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term hypercaloric feeding (30% extra calories from fat and fructose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypercaloric feeding
Number of subjects: 0
Study: 22760568

Group type: EXPERIMENTAL
Intervention: 4000 IU/d vitamin D3 supplementation for 1 year
Number of subjects: 47
Study: 22761257

Group type: EXPERIMENTAL
Intervention: Leukotriene B4 (LTB4) at 10 ng/ml in OSA patient monocytes
Number of subjects: 120

Group type: COMPARATOR
Intervention: In vitro exposure of PMNs from controls to intermittent hypoxia (IH)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PMNs from OSA patients
Number of subjects: 120
Study: 22761263

Group type: EXPERIMENTAL
Intervention: Silicon-based quantum dots (QDs)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Inactive gold-based QD
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 22761653

Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg daily) and IGRT (50 Gy)
Number of subjects: 25
Study: 22762314

Group type: EXPERIMENTAL
Intervention: Eltrombopag (50 mg daily, increased to 150 mg as needed for 12 weeks)
Number of subjects: 25
Study: 22762417

Group type: EXPERIMENTAL
Intervention: 7F EXOSEAL™ Vascular Closure Device (VCD)
Number of subjects: 60
Study: 22762561

Group type: EXPERIMENTAL
Intervention: Haemophilic subjects
Number of subjects: 104

Group type: COMPARATOR
Intervention: Non-haemophilic subjects
Number of subjects: 104
Study: 22762711

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 1195

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 1195
Study: 22763262

Group type: EXPERIMENTAL
Intervention: Strattice (non-cross-linked, porcine, acellular dermal matrix)
Number of subjects: 80
Study: 22763609

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² intravenously every 21 days until progression or unacceptable toxicity
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 48
Study: 22764211

Group type: EXPERIMENTAL
Intervention: BM-MNC-treated group
Number of subjects: 20
Study: 22766223

Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH) at 100 μg/day for 28 days
Number of subjects: 13
Study: 22766247

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted A/H1N1 influenza vaccine, Focetria
Number of subjects: 7943
Study: 22766338

Group type: EXPERIMENTAL
Intervention: Endurance training (ET) for 4 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 40
Study: 22766773

Group type: EXPERIMENTAL
Intervention: Enzastaurin (500 mg QD, 250 mg BID, 375 mg BID, 500 mg BID, 750 mg BID) in combination with Bevacizumab (5 mg/kg every 2 weeks, 10 mg/kg every 2 weeks, or 15 mg/kg every 3 weeks)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Enzastaurin (750 mg BID) in combination with any tested dose/schedule of Bevacizumab
Number of subjects: 67
Study: 22767640

Group type: EXPERIMENTAL
Intervention: B lymphocyte depletion therapy (iv rituximab 1 g on days 1 and 15 after 125 mg iv methylprednisolone)
Number of subjects: 6
Study: 22768052

Group type: EXPERIMENTAL
Intervention: AMA1 vaccine (10 µg) with Alhydrogel
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: AMA1 vaccine (50 µg) with Alhydrogel
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: AMA1 vaccine (10 µg) with Montanide ISA 720
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: AMA1 vaccine (50 µg) with Montanide ISA 720
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: AMA1 vaccine (10 µg) with AS02
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: AMA1 vaccine (50 µg) with AS02
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Growth Inhibition Assay (GIA)
Number of subjects: 47
Study: 22769055

Group type: EXPERIMENTAL
Intervention: 600mcg sublingual misoprostol
Number of subjects: 213

Group type: COMPARATOR
Intervention: 800mcg sublingual misoprostol
Number of subjects: 213
Study: 22770643

Group type: EXPERIMENTAL
Intervention: Dronedarone on top of standard of care (SOC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dronedarone on top of SOC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 0
Study: 22770644

Group type: EXPERIMENTAL
Intervention: Oral linezolid (600 mg q12h)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Intravenous vancomycin (15 mg/kg q12h)
Number of subjects: 92
Study: 22771101

Group type: EXPERIMENTAL
Intervention: Deep small-bowel spiral enteroscopy
Number of subjects: 78
Study: 22772084

Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Cardiac dysrhythmias
Number of subjects: 183

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 183
Study: 22772403

Group type: EXPERIMENTAL
Intervention: Systematic wound biopsies (two 6-mm punch biopsies, one at the wound edge and one in the wound bed)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Systematic wound biopsies
Number of subjects: 144
Study: 22773225

Group type: EXPERIMENTAL
Intervention: Weight Loss + Physical Activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical Activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Successful Aging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-efficacy mediation
Number of subjects: 0
Study: 22773521

Group type: EXPERIMENTAL
Intervention: HbA1c ≥ 6.5% (48 mmol/mol)
Number of subjects: 8696

Group type: EXPERIMENTAL
Intervention: Two HbA1c thresholds: HbA1c ≤ 5.8% (rule-in, 40 mmol/mol) and HbA1c ≥ 6.8% (rule-out, 51 mmol/mol)
Number of subjects: 8696

Group type: EXPERIMENTAL
Intervention: Two cut-point threshold
Number of subjects: 8696

Group type: EXPERIMENTAL
Intervention: Risk score to determine HbA1c testing
Number of subjects: 8696
Study: 22773528

Group type: EXPERIMENTAL
Intervention: Implanted 8-channel functional electrical stimulation (FES) system for standing
Number of subjects: 0
Study: 22775568

Group type: EXPERIMENTAL
Intervention: Eosinophilic subjects (CSS and HES)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 276
Study: 22775772

Group type: EXPERIMENTAL
Intervention: Cognitive control intervention (fMRI Stroop task)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (20 participants)
Number of subjects: 20
Study: 22776196

Group type: EXPERIMENTAL
Intervention: recombinant factor IX (nonacog alfa)
Number of subjects: 0
Study: 22776426

Group type: EXPERIMENTAL
Intervention: Vaccination with three HLA-A24-binding peptides (TTK, LY6K, IMP3) administered with IFA weekly
Number of subjects: 60
Study: 22776937

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 0
Study: 22777035

Group type: EXPERIMENTAL
Intervention: Dorsal homodigital island flap
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cross-finger flap
Number of subjects: 15
Study: 22777094

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted A/H5N1 influenza vaccine booster dose
Number of subjects: 0
Study: 22777097

Group type: EXPERIMENTAL
Intervention: Boosted group (received interim booster dose at year 5)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Unboosted group (did not receive interim booster dose)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Unboosted group (after HBV vaccine challenge dose at year 20)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Boosted group (after HBV vaccine challenge dose at year 20)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Post administration of the challenge dose
Number of subjects: 44
Study: 22777131

Group type: EXPERIMENTAL
Intervention: Levetiracetam (55 mg/kg/d) for 30 days starting within 8 hours after injury
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Levetiracetam (55 mg/kg/d)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Levetiracetam treatment group
Number of subjects: 126

Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Levetiracetam treatment
Number of subjects: 126
Study: 22777623

Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg or 10 mg once daily for 24 weeks
Number of subjects: 12
Study: 22780885

Group type: EXPERIMENTAL
Intervention: Vitamin D (daily dose of 3533 IU, increased to 8533 IU after the first five participants) and 530 mg elemental Ca daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vitamin D and Calcium supplementation
Number of subjects: 12
Study: 22780919

Group type: EXPERIMENTAL
Intervention: CAR-engineered T cells targeting EGFRvIII
Number of subjects: 0
Study: 22781225

Group type: EXPERIMENTAL
Intervention: NK cells from cases (HIV-infected women)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rhIL-2-activated NK cells from cases
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NK cells from cases
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NK cell responses to autologous HIV-infected cells
Number of subjects: 60
Study: 22782568

Group type: EXPERIMENTAL
Intervention: MR-CVW
Number of subjects: 17

Group type: COMPARATOR
Intervention: IVUS
Number of subjects: 17
Study: 22782731

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor use
Number of subjects: 24471

Group type: COMPARATOR
Intervention: No proton pump inhibitor use
Number of subjects: 24471

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor use (self controlled case series)
Number of subjects: 24471

Group type: EXPERIMENTAL
Intervention: Other 2C19 inhibitors/non-inhibitors (self controlled case series)
Number of subjects: 24471
Study: 22783896

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study: 22784036

Group type: EXPERIMENTAL
Intervention: CSF concentrations of amyloid-beta (Aβ)(42)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Aβ deposition measured by positron-emission tomography
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: CSF concentrations of tau protein and brain atrophy
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Cerebral hypometabolism and impaired episodic memory
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Global cognitive impairment measured by Mini-Mental State Examination and Clinical Dementia Rating scale
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Diagnostic criteria for dementia
Number of subjects: 128
Study: 22784116

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 38
Study: 22785351

Group type: EXPERIMENTAL
Intervention: ERBB network therapies, specific details not available
Number of subjects: 0
Study: 22786687

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 21107
Study: 22786877

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 45
Study: 22787016

Group type: EXPERIMENTAL
Intervention: SPIO-labeled cells
Number of subjects: 1
Study: 22788989

Group type: EXPERIMENTAL
Intervention: Neoadjuvant dose-escalated IMRT (50-56 Gy) followed by surgery and IORT (10-12 Gy)
Number of subjects: 37
Study: 22789058

Group type: EXPERIMENTAL
Intervention: Hepatocyte transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 0
Study: 22789619

Group type: EXPERIMENTAL
Intervention: Antioxidants (Vitamin E, Glutathione, Uric Acid, Total Antioxidant Capacity)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Antioxidants (Uric Acid)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Antioxidants (Vitamin E)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Total Antioxidant Capacity (TEAC)
Number of subjects: 15
Study: 22789807

Group type: EXPERIMENTAL
Intervention: High fibre intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total carbohydrate, sucrose, and fructose intakes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention to increase fibre intake while restricting refined sugar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dietary recommendations for children
Number of subjects: 0
Study: 22789936

Group type: EXPERIMENTAL
Intervention: Carotid plaque burden
Number of subjects: 6101

Group type: EXPERIMENTAL
Intervention: cIMT
Number of subjects: 6101

Group type: EXPERIMENTAL
Intervention: AAD
Number of subjects: 6101

Group type: EXPERIMENTAL
Intervention: ABI
Number of subjects: 6101

Group type: COMPARATOR
Intervention: Coronary artery calcium score (CACS)
Number of subjects: 6101

Group type: EXPERIMENTAL
Intervention: Carotid plaques
Number of subjects: 6101

Group type: EXPERIMENTAL
Intervention: Abnormal ABI
Number of subjects: 6101

Group type: EXPERIMENTAL
Intervention: AAD >20 mm
Number of subjects: 6101
Study: 22790549

Group type: EXPERIMENTAL
Intervention: Morning serum melatonin levels in patients with MDD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nocturnal serum melatonin levels in patients with MDD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nocturnal serum melatonin levels in depressed women
Number of subjects: 0
Study: 22790832

Group type: EXPERIMENTAL
Intervention: Participation in genetic counseling for BRCA1/2 mutations
Number of subjects: 135

Group type: COMPARATOR
Intervention: Declined pre-test counseling
Number of subjects: 135
Study: 22790881

Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 440

Group type: COMPARATOR
Intervention: Living with spouse and/or children
Number of subjects: 440
Study: 22791040

Group type: EXPERIMENTAL
Intervention: Lumbar discectomy at various academic spine centers
Number of subjects: 792
Study: 22792000

Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release (50-250 mg bid)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release and immediate release (50 mg ≤twice/day; ≥4 hours apart)
Number of subjects: 195
Study: 22794705

Group type: EXPERIMENTAL
Intervention: Localization lumpectomy under stereotactic guidance
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Presence of in situ disease
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: High tumor grade
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Larger tumor size
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Multifocal disease
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Presence of mammographic microcalcifications
Number of subjects: 305
Study: 22794786

Group type: EXPERIMENTAL
Intervention: Viral gene therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 0
Study: 22795276

Group type: EXPERIMENTAL
Intervention: CP stent
Number of subjects: 105
Study: 22795984

Group type: EXPERIMENTAL
Intervention: Internet walking program and pedometer
Number of subjects: 27
Study: 22796509

Group type: EXPERIMENTAL
Intervention: High tibial osteotomy (HTO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: dGEMRIC scan
Number of subjects: 10
Study: 22797701

Group type: EXPERIMENTAL
Intervention: Open mesh or sutured repair for small umbilical or epigastric hernias
Number of subjects: 132
Study: 22798017

Group type: EXPERIMENTAL
Intervention: Serum sTREM-1 levels
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: TREM-1 SNP rs2234237
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 160
Study: 22798253

Group type: COMPARATOR
Intervention: Non-exercise control treatment (n=92)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (50% of VO(2peak)) 4 KKW (n=151)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (50% of VO(2peak)) 8 KKW (n=99)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (50% of VO(2peak)) 12 KKW (n=95)
Number of subjects: 437
Study: 22800647

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study: 22800719

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 2854

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 2854
Study: 22801008

Group type: EXPERIMENTAL
Intervention: Nasal mucosa temperature
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nasal obstruction
Number of subjects: 35
Study: 22801061

Group type: EXPERIMENTAL
Intervention: Glasgow Blatchford score (GBS)
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: age-extended GBS (EGBS)
Number of subjects: 831

Group type: COMPARATOR
Intervention: Rockall score
Number of subjects: 831

Group type: COMPARATOR
Intervention: Baylor bleeding score
Number of subjects: 831

Group type: COMPARATOR
Intervention: Cedars-Sinai Medical Center predictive index
Number of subjects: 831
Study: 22801963

Group type: EXPERIMENTAL
Intervention: GCLAC (clofarabine, high-dose cytarabine, and granulocyte colony-stimulating factor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FA (fludarabine and cytarabine) and FLAG (fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor)
Number of subjects: 0
Study: 22802929

Group type: EXPERIMENTAL
Intervention: 2009 AS03-adjuvanted pandemic vaccine
Number of subjects: 13887

Group type: COMPARATOR
Intervention: Seasonal trivalent inactivated influenza vaccine (TIV)
Number of subjects: 13887
Study: 22803961

Group type: EXPERIMENTAL
Intervention: Intensified risk factor management
Number of subjects: 41
Study: 22804876

Group type: EXPERIMENTAL
Intervention: 75-g oral glucose tolerance test
Number of subjects: 74
Study: 22805056

Group type: EXPERIMENTAL
Intervention: Wuerzburg bleb classification score ≥ 8 points
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Wuerzburg bleb classification score ≥ 7 points
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Occurrence of microcysts on the filtering bleb
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Target pressure (≤ 21mmHg)
Number of subjects: 57
Study: 22805291

Group type: EXPERIMENTAL
Intervention: Trametinib 2 mg once daily (recommended phase 2 dose)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Trametinib 3 mg once daily (maximum tolerated dose)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Trametinib 2 mg once daily
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 206
Study: 22805292

Group type: EXPERIMENTAL
Intervention: Trametinib (oral MEK inhibitor)
Number of subjects: 97
Study: 22805466

Group type: EXPERIMENTAL
Intervention: FeNO(50)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: J(NO)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: C(alv)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Indoor allergens sensitivity
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: C(alv) levels
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: J(NO) levels
Number of subjects: 36
Study: 22805548

Group type: EXPERIMENTAL
Intervention: Thoracic impedance and oximetry in a multi-modal ECG Holter system
Number of subjects: 0
Study: 22805550

Group type: EXPERIMENTAL
Intervention: α-Galactosidase A (aGAL A) activity measured using a dried bloodspot test (DBS) and mutation analysis of the GLA gene in males; mutation analysis as primary screening tool in females.
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Screening for Fabry disease (FD) in patients with arterial hypertension (AHT) or LVH.
Number of subjects: 540
Study: 22805651

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) scan in asymptomatic FDRs
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (616 individuals with no family history of cardiovascular disease)
Number of subjects: 57
Study: 22808058

Group type: EXPERIMENTAL
Intervention: Hepcidin-25 levels
Number of subjects: 405
Study: 22809118

Group type: EXPERIMENTAL
Intervention: sTREM-1
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: PCT
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 144
Study: 22809908

Group type: EXPERIMENTAL
Intervention: Electronic automated advisory vital signs monitors (intervention)
Number of subjects: 18605
Study: 22810810

Group type: EXPERIMENTAL
Intervention: Targeting members of the lysyl oxidase (LOX) family of proteins
Number of subjects: 0
Study: 22811928

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 22812667

Group type: EXPERIMENTAL
Intervention: Unilateral subretinal injection in a clinical gene therapy trial
Number of subjects: 3
Study: 22812719

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms
Number of subjects: 31
Study: 22813439

Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitor (PPI) test with esomeprazole (40 mg once daily for 2 weeks)
Number of subjects: 308
Study: 22813607

Group type: EXPERIMENTAL
Intervention: Serum S100B levels at all time points and neuron-specific enolase levels on days 1 and 3
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Admission S100B level
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Day 3 S100B level
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Clinical and biomarker data
Number of subjects: 195
Study: 22813874

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (target core temperature of 32-34°C, cooling duration of 12-72 hours)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Collapse-to-ROSC interval ≤16 min
Number of subjects: 372
Study: 22814783

Group type: EXPERIMENTAL
Intervention: Serious infection
Number of subjects: 5745

Group type: COMPARATOR
Intervention: No serious infection
Number of subjects: 5745
Study: 22815471

Group type: EXPERIMENTAL
Intervention: FASY (Women Taking Action For Their Health) intervention
Number of subjects: 200